Apollo Endosurgery Inc (APEN) Major Shareholder Stonepine Capital, L.P. Acquires 5,163 Shares

Apollo Endosurgery Inc (NASDAQ:APEN) major shareholder Stonepine Capital, L.P. acquired 5,163 shares of the company’s stock in a transaction dated Saturday, December 29th. The stock was acquired at an average price of $5.56 per share, with a total value of $28,706.28. Following the purchase, the insider now owns 2,560,314 shares in the company, valued at approximately $14,235,345.84. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Stonepine Capital, L.P. also recently made the following trade(s):

  • On Wednesday, January 3rd, Stonepine Capital, L.P. acquired 22,845 shares of Apollo Endosurgery stock. The stock was acquired at an average price of $5.71 per share, with a total value of $130,444.95.
  • On Tuesday, December 26th, Stonepine Capital, L.P. acquired 5,287 shares of Apollo Endosurgery stock. The stock was acquired at an average price of $5.00 per share, with a total value of $26,435.00.
  • On Wednesday, December 20th, Stonepine Capital, L.P. acquired 45,434 shares of Apollo Endosurgery stock. The stock was acquired at an average price of $4.50 per share, with a total value of $204,453.00.
  • On Friday, December 22nd, Stonepine Capital, L.P. acquired 185,157 shares of Apollo Endosurgery stock. The stock was acquired at an average price of $4.85 per share, with a total value of $898,011.45.

Shares of Apollo Endosurgery Inc (APEN) traded down $0.07 during mid-day trading on Wednesday, hitting $5.82. 66,758 shares of the stock were exchanged, compared to its average volume of 76,200. Apollo Endosurgery Inc has a 52 week low of $3.55 and a 52 week high of $19.95. The firm has a market cap of $100.63, a PE ratio of -0.27 and a beta of 0.44. The company has a current ratio of 2.54, a quick ratio of 2.00 and a debt-to-equity ratio of 0.58.

A number of equities analysts have recently issued reports on the stock. ValuEngine upgraded shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research note on Wednesday. Northland Securities assumed coverage on shares of Apollo Endosurgery in a research note on Tuesday, September 26th. They issued an “outperform” rating and a $12.00 price objective for the company. Finally, Zacks Investment Research cut shares of Apollo Endosurgery from a “buy” rating to a “hold” rating in a research note on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $9.44.

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new stake in shares of Apollo Endosurgery during the 3rd quarter worth about $119,000. Woodmont Investment Counsel LLC acquired a new stake in shares of Apollo Endosurgery during the 3rd quarter worth about $220,000. Russell Investments Group Ltd. acquired a new stake in shares of Apollo Endosurgery during the 3rd quarter worth about $1,288,000. King Luther Capital Management Corp acquired a new stake in shares of Apollo Endosurgery during the 3rd quarter worth about $2,567,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Apollo Endosurgery during the 3rd quarter worth about $11,067,000. Institutional investors own 23.67% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.chaffeybreeze.com/2018/01/03/apollo-endosurgery-inc-apen-major-shareholder-stonepine-capital-l-p-acquires-5163-shares.html.

Apollo Endosurgery Company Profile

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply